Hib-DTaP vaccine (Beijing Minhai Biotechnology)

无细胞百白破b型流感嗜血杆菌联合疫苗（北京民海生物科技）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHib-DTaP vaccine (Beijing Minhai Biotechnology)
Drug Alias NameHib-DTaP-acellular-vaccine- Beijing Minhai Biotechnology美联吉泰
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Combination vaccineVaccines > Biological material > Toxoid vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsTetanusDiphtheriaHaemophilus Infections +[4] 
Global Approved IndicationsTetanusDiphtheriaHaemophilus Infections +[4] 
Approved Indications in ChinaTetanusDiphtheriaHaemophilus Infections +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date2012/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Minhai Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Minhai Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsTetanusDiphtheriaHaemophilus Infections +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ07AG
Related LinksWikipedia